35216-39-8

Basic information

• Product Name: 3-(METHYLSULFONYL)ANILINE
• Synonyms: P-Toluene Suphonamide (PTSA);3-(Methylsulphonyl)aniline;3-Aminophenyl methyl sulphone;3-(methylsulfonyl)Benzenamine;m-(Methylsulfonyl)aniline;3-Aminophenyl methyl sulfone;3-Methylsulfonylphenylamine
• CAS NO: 35216-39-8
• Molecular Formula: C₇H₉NO₂S
• Molecular Weight: 171.22
• Mol File: 35216-39-8.mol
• Article Data: 13

Chemical Properties

• Melting Point: 72 °C
• Boiling Point: 403.3°C at 760 mmHg
• Flash Point: 197.7°C
• Appearance: /
• Density: 1.282g/cm³
• Vapor Pressure: 1.03E-06mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.66±0.10(Predicted)
• CAS DataBase Reference: 3-(METHYLSULFONYL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(METHYLSULFONYL)ANILINE(35216-39-8)
• EPA Substance Registry System: 3-(METHYLSULFONYL)ANILINE(35216-39-8)

Safety Data

• Hazardous Substances Data: 35216-39-8(Hazardous Substances Data)

Usage

Description

3-(METHYLSULFONYL)ANILINE, also known as 3-(Methylsulfonyl)aniline, is an organic compound with the chemical formula C7H9NO2S. It is a colorless to pale yellow liquid with a slight amine-like odor. 3-(METHYLSULFONYL)ANILINE is characterized by its methylsulfonyl group attached to the aniline structure, which provides unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
3-(METHYLSULFONYL)ANILINE is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with potential therapeutic applications.
Used in the Preparation of Substituted Pyrazolopyrimidines:
3-(METHYLSULFONYL)ANILINE is used as a starting material for the preparation of substituted pyrazolopyrimidines, which are known as IRAK4 kinase inhibitors. These inhibitors play a crucial role in the regulation of inflammatory responses and have potential applications in the treatment of various inflammatory diseases and conditions.

InChI:InChI=1/C7H9NO2S/c1-11(9,10)7-4-2-3-6(8)5-7/h2-5H,8H2,1H3

Upstream product

• 33951-33-6 1-bromo-2-(methylsulfonyl)benzene 
• 2976-32-1 1-methanesulfonyl-3-nitro-benzene 
• 1783-81-9 3-methylmercaptoaniline 
• 3937-95-9 3-Nitrophenylsulfonylessigsaeure 
• 13257-95-9 3-nitrobenzenesulfinic acid 
• 19614-16-5 2-bromo-1-(methylsulfanyl)benzene 
• 20277-69-4 sodium methansulfinate 
• 591-19-5 m-Bromoaniline 
• 3112-85-4 methylphenylsulfonate 
• 124-63-0 methanesulfonyl chloride 
• 626-01-7 3-Iodoaniline 

Downstream Products

• 14763-61-2 3-(methylsulfonyl)phenol 
• 22821-75-6 3-(methylsulfonyl)benzonitrile 
• 107516-85-8 (3-methanesulfonyl-phenyl)-phenyl-diazene 
• 125802-65-5 (9-Benzyl-2-chloro-9H-purin-6-yl)-(3-methanesulfonyl-phenyl)-amine 
• 861136-92-7 (3-methanesulfonyl-phenyl)-(1-methoxy-5,6,7,8-tetrahydro-isoquinolin-4-yl)-amine 
• 861136-87-0 (3-methansulfonyl-phenyl)-(1-methoxy-3-methyl-5,6,7,8-tetrahydro-isoquinolin-4-yl)-amine 
• 54743-68-9 1-isothiocyanato-3-(methylsulfonyl)benzene 

Relevant articles and documents

WDR5-MYC INHIBITORS

Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE

Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having C—N, C—O, C—S and other bonds.

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.